Mefruside
Chemical compound
- C03BA05 (WHO)
- In general: ℞ (Prescription only)
- 4-chloro-N1-methyl-N1-[(2-methyltetrahydrofuran-2-yl)methyl]benzene-1,3-disulfonamide
- 7195-27-9
Y
- 4047
- 3907
N
- X1NS9SNS92
- D01877 Y
- DTXSID0048844
- Interactive image
- CC1(CCCO1)CN(C)S(=O)(=O)C2=CC(=C(C=C2)Cl)S(=O)(=O)N
InChI
- InChI=1S/C13H19ClN2O5S2/c1-13(6-3-7-21-13)9-16(2)23(19,20)10-4-5-11(14)12(8-10)22(15,17)18/h4-5,8H,3,6-7,9H2,1-2H3,(H2,15,17,18)N
- Key:SMNOERSLNYGGOU-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Mefruside (INN) is a diuretic indicated for the treatment of edema and hypertension.[1]
It was developed by Bayer A.G. and is sold under the tradename Baycaron.
References
- ^ Allen HB, Lee DA (1973). "A general practice assessment of mefruside ('Baycaron') in the treatment of oedema and hypertension". Curr Med Res Opin. 1 (9): 547–53. doi:10.1185/03007997309111720. PMID 4779251.
- v
- t
- e
Diuretics (C03)
(and etacrynic acid)
| CA inhibitors (at PT) | |
|---|---|
| Loop (Na-K-Cl at AL) | |
| Thiazides (Na-Cl at DCT, Calcium-sparing) | |
| Thiazide-likes (primarily DCT) |
| ESC blockers | |
|---|---|
| Aldosterone antagonists |
(DCT and CD)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
